PROVIDENCE, R.I., Dec. 9, 2025 /PRNewswire/ -- EpiVax, Inc., with U.S. Food and Drug Administration (FDA) and CUBRC, Inc. (Buffalo, NY) scientist collaborators, announces the publication of a study ...
The use of biologic-based therapeutics has revolutionized our ability to treat complex diseases such as cancer- and autoimmune-related disorders. Biologic-based therapeutics are known to generate anti ...
PROVIDENCE, R.I., Dec. 8, 2025 /PRNewswire/ -- EpiVax, Inc., with U.S. Food and Drug Administration (FDA) and CUBRC, Inc. (Buffalo, NY) scientist collaborators ...
EpiVax, Inc., with US Food and Drug Administration (FDA) and CUBRC, Inc. (Buffalo, NY) scientist collaborators, announces the publication of a study titled “Immunogenicity Risk Assessment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results